Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nycomed Prepares To Launch First Nonprescription PPI With EU-Wide Approval

This article was originally published in The Tan Sheet

Executive Summary

Nycomed is gearing up to launchPantozol Control (pantoprazole 20 mg) later this year when the firm expects an approval for European Union nonprescription marketing authorization

You may also be interested in...



Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways

EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.

Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways

EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.

Japan's Takeda Reportedly Offering $12B For Europe's Nycomed

Japan's largest drug maker, Takeda Pharmaceuticals Co. Ltd., may be close to buying private-equity owned Nycomed AS, based in Switzerland, for about $12 billion

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel